About: Kangfuxinye Enema Combined with Mesalamine for Ulcerative Colitis: A Systematic Review and GRADE Approach

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Kangfuxinye Enema Combined with Mesalamine for Ulcerative Colitis: A Systematic Review and GRADE Approach Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Kangfuxinye Enema Combined with Mesalamine for Ulcerative Colitis: A Systematic Review and GRADE Approach
Creator	Kang, De-Ying Ren, Peng-Wei Hong, Qi Wen, Shu Wang, Dan-Dan Shan, Jing-Yan Yang, Wen-Jie Zhang, Ru-Wen
Source	PMC
abstract	OBJECTIVES: To critically appraise the efficacy and safety of Kangfuxinye enema combined with mesalamine for the ulcerative colitis (UC) patients and in addition to grade the quality of evidence by using the GRADE (grading of recommendations, assessment, development, and evaluation) approach. METHODS: A literature search was performed in the Cochrane Library, MEDLINE, EMBASE, CBM, CNKI, VIP, and WanFang Databases. The search restrictions were patients with UC and RCTs. Studies including other treatments except Kangfuxinye with mesalamine were excluded. RESULTS: Nineteen studies met the inclusion criteria. We found significant benefits of Kangfuxinye combined with mesalamine against mesalamine alone in improving response rate as well as reducing the recurrence rate and inflammation rate; meanwhile, the increase of the adverse events rate was not observed. Furthermore, the symptoms remission rate and the cure time were insignificant statistically. Additionally, GRADE results indicated that the quality of evidence regarding the above 6 outcomes was rated from very low to moderate quality. CONCLUSIONS: Although Kangfuxinye enema seems effective and safe for treating UC patients in this systematic review, Kangfuxinye enema combined with mesalamine was weakly recommended due to very low to moderate quality of available evidence by the GRADE approach.
has issue date	2017-08-07(xsd:dateTime)
bibo:doi	10.1155/2017/6019530
bibo:pmid	28848616
has license	cc-by
sha1sum (hex)	c60b9bd1c5edac3f1f4916571a10a6daf9b569a6
schema:url	https://doi.org/10.1155/2017/6019530
resource representing a document's title	Kangfuxinye Enema Combined with Mesalamine for Ulcerative Colitis: A Systematic Review and GRADE Approach
has PubMed Central identifier	PMC5564127
has PubMed identifier	28848616
schema:publication	Evid Based Complement Alternat Med
resource representing a document's body	covid:c60b9bd1c5edac3f1f4916571a10a6daf9b569a6#body_text
is schema:about of	named entity 'ADVERSE EVENTS RATE' named entity 'PERFORMED' named entity 'SYSTEMATIC REVIEW' named entity 'QUALITY OF EVIDENCE' named entity 'USING' named entity 'EXCLUDED' named entity 'LIBRARY' named entity 'DUE TO' named entity 'ASSESSMENT' named entity 'INCLUSION CRITERIA' named entity 'QUALITY' named entity 'EXCEPT' named entity 'FOUND' named entity 'CONCLUSIONS' named entity 'ENEMA' named entity 'SAFE' named entity 'LITERATURE SEARCH' named entity 'RCTS' named entity 'TREATMENTS' named entity 'SEARCH' named entity 'INFLAMMATION' named entity 'OUTCOMES' named entity 'INDICATED' named entity 'PATIENTS' named entity 'INCREASE' named entity 'MEDLINE' named entity 'BENEFITS' named entity 'OBJECTIVES' named entity 'REDUCING' named entity 'IMPROVING' named entity 'SYSTEMATIC REVIEW' named entity 'GRADE APPROACH' named entity 'GRADE' named entity 'ADDITION' named entity 'SAFETY' named entity 'SYMPTOMS' named entity 'RECOMMENDED' named entity 'ENEMA' named entity 'MESALAMINE' named entity 'COMBINED' named entity 'NINETEEN' named entity 'RECOMMENDATIONS' named entity 'AVAILABLE' named entity 'TREATING' named entity 'ULCERATIVE COLITIS' named entity 'RECURRENCE RATE' named entity 'MET' named entity 'EVALUATION' named entity 'STATISTICALLY' named entity 'VIP' named entity 'COMBINED' named entity 'RESPONSE RATE' named entity 'MESALAMINE' named entity 'APPROACH' named entity 'EFFECTIVE' named entity 'CURE' named entity 'INCLUDING' named entity 'ULCERATIVE COLITIS' named entity 'EFFICACY' named entity 'MODERATE' named entity 'DATABASES' named entity 'STUDIES' named entity 'RATE' named entity 'INSIGNIFICANT' named entity 'EMBASE' named entity 'DEVELOPMENT' named entity 'NOT OBSERVED' named entity 'SIGNIFICANT' named entity 'GRADE APPROACH' named entity 'RESULTS' named entity 'REMISSION RATE' named entity 'METHODS' named entity 'EVIDENCE' named entity 'TIME'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software